BTIG Research reiterated their hold rating on shares of Edwards Lifesciences (NYSE:EW) in a research report report published on Thursday, AnalystRatings.com reports.

A number of other research analysts have also recently weighed in on EW. Deutsche Bank lifted their target price on shares of Texas Instruments from $100.00 to $110.00 and gave the company a hold rating in a research note on Wednesday, April 24th. JPMorgan Chase & Co. restated a buy rating on shares of SAGE Therapeutics in a research note on Wednesday, July 24th. BMO Capital Markets set a $81.00 target price on shares of Kilroy Realty and gave the company a buy rating in a research note on Wednesday, July 24th. Stifel Nicolaus cut shares of Owens Corning from a buy rating to a hold rating and set a $52.45 target price on the stock. in a research note on Wednesday, April 24th. Finally, Jefferies Financial Group boosted their price target on shares of Texas Instruments from $137.00 to $170.00 and gave the stock a buy rating in a research note on Wednesday, July 24th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $204.74.

EW opened at $212.85 on Thursday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.69 and a current ratio of 3.38. Edwards Lifesciences has a fifty-two week low of $134.53 and a fifty-two week high of $219.71. The company’s fifty day moving average price is $190.15. The stock has a market cap of $44.38 billion, a PE ratio of 45.29, a price-to-earnings-growth ratio of 2.68 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.33 by $0.05. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the previous year, the company earned $1.24 EPS. Edwards Lifesciences’s revenue for the quarter was up 15.2% on a year-over-year basis. On average, equities research analysts anticipate that Edwards Lifesciences will post 5.34 EPS for the current year.

In other news, VP Catherine M. Szyman sold 1,474 shares of the business’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $177.92, for a total value of $262,254.08. Following the sale, the vice president now directly owns 21,396 shares in the company, valued at approximately $3,806,776.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 3,000 shares of the business’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $169.60, for a total transaction of $508,800.00. Following the completion of the sale, the vice president now owns 20,674 shares in the company, valued at $3,506,310.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 147,691 shares of company stock worth $27,365,639. Corporate insiders own 1.63% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its holdings in shares of Edwards Lifesciences by 4.7% in the 1st quarter. BlackRock Inc. now owns 17,211,498 shares of the medical research company’s stock worth $3,293,075,000 after buying an additional 780,079 shares during the last quarter. FMR LLC increased its holdings in shares of Edwards Lifesciences by 7.9% in the 1st quarter. FMR LLC now owns 8,175,796 shares of the medical research company’s stock worth $1,564,274,000 after buying an additional 598,976 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Edwards Lifesciences by 40.2% in the 1st quarter. Jennison Associates LLC now owns 5,763,824 shares of the medical research company’s stock worth $1,102,792,000 after buying an additional 1,651,691 shares during the last quarter. Norges Bank bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $559,646,000. Finally, Geode Capital Management LLC increased its holdings in shares of Edwards Lifesciences by 7.4% in the 4th quarter. Geode Capital Management LLC now owns 2,942,494 shares of the medical research company’s stock worth $449,976,000 after buying an additional 202,248 shares during the last quarter. Hedge funds and other institutional investors own 81.95% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: Why do analysts give a neutral rating?

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.